Macrophage Migration Inhibitory Factor Pipeline Assessment 2017

    480
    0
    SHARE

    Macrophage Migration Inhibitory Factor Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Macrophage Migration Inhibitory Factor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    Macrophage Migration Inhibitory Factor pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Request for a sample copy at: https://www.marketinsightsreports.com/reports/110233836/macrophage-migration-inhibitory-factor-glycosylation-inhibiting-factor-or-l-dopachrome-isomerase-or-l-dopachrome-tautomerase-or-phenylpyruvate-tautomerase-or-mif-or-ec-5-3-2-1-or-ec-5-3-3-12-pipeline-review-h2-2017/inquiry

    Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) – Macrophage migration inhibitory factor (MIF) also known as glycosylation-inhibiting factor (GIF) is a protein that is encoded by the MIF gene. Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine produced by the pituitary gland and multiple cell types, including macrophages, dendritic cells (DC) and T-cells. Upon releases MIF modulates the expression of several inflammatory molecules, such as TNF-?, nitric oxide and cyclooxygenase 2 (COX-2). MIF is an important regulator of innate immunity. Antigens stimulate white blood cells to release MIF into the blood stream. The circulating MIF binds to CD74 on other immune cells and trigger an acute immune response. MIF plays a role in the regulation of macrophage function in host defense through the suppression of anti-inflammatory effects of glucocorticoid.

    Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Gastrointestinal, Immunology, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders, Dermatology and Respiratory which include indications Prostate Cancer, Glomerulonephritis, Inflammatory Bowel Disease, Pulmonary Arterial Hypertension, Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes), Alcohol Addiction, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Asthma, Atopic Dermatitis, Autoimmune Disorders, Crohn’s Disease (Regional Enteritis), Drug Addiction, Globoid Cell Leukodystrophy (Krabbe Disease), Multiple Sclerosis, Myocardial Infarction, Obesity, Opium Withdrawal Syndrome, Primary Progressive Multiple Sclerosis (PPMS), Psoriasis, Recurrent Glioblastoma Multiforme (GBM), Secondary Progressive Multiple Sclerosis (SPMS), Solid Tumor, Systemic Lupus Erythematosus, Traumatic Brain Injury, Type 2 Diabetes and Ulcerative Colitis.

    The latest report Macrophage Migration Inhibitory Factor – Pipeline Review, H2 2017, outlays comprehensive information on the Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Macrophage Migration Inhibitory Factor (Glycosylation Inhibiting Factor or L Dopachrome Isomerase or L Dopachrome Tautomerase or Phenylpyruvate Tautomerase or MIF or EC 5.3.2.1 or EC 5.3.3.12) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Browse full Report at: https://www.marketinsightsreports.com/reports/110233836/macrophage-migration-inhibitory-factor-glycosylation-inhibiting-factor-or-l-dopachrome-isomerase-or-l-dopachrome-tautomerase-or-phenylpyruvate-tautomerase-or-mif-or-ec-5-3-2-1-or-ec-5-3-3-12-pipeline-review-h2-2017

    Scope of this report:

    • The pipeline guide provides a snapshot of the global therapeutic landscape of Macrophage Migration Inhibitory Factor. The pipeline guide reviews pipeline therapeutics for Macrophage Migration Inhibitory Factor by companies and universities/research institutes based on information derived from company and industry-specific sources.
    • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    • The pipeline guide reviews key companies involved in Macrophage Migration Inhibitory Factor therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Macrophage Migration Inhibitory Factor therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Macrophage Migration Inhibitory Factor.
    • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    • Find and recognize significant and varied types of therapeutics under development for Macrophage Migration Inhibitory Factor. Classify potential new clients or partners in the target demographic.
    • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    • Formulate corrective measures for pipeline projects by understanding Macrophage Migration Inhibitory Factor pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here